Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 3 Medical Devices Recommended for Approval
May 24, 2010
- Eisai: Aricept, Cancer-Related Products Drive Sales Up 2.7%
May 24, 2010
- Taiyo Yakuhin Recalls Another Product
May 24, 2010
- MTPC: Pharma Sales Up 2.2% Driven by Remicade
May 24, 2010
- GSK's Ofatumumab Receives Conditional Approval in EU
May 24, 2010
- DSP: Overseas Subsidiaries Boost Sales
May 24, 2010
- New Indication for Actemra Approved in Europe
May 24, 2010
- Shionogi: Crestor, US Subsidiary Drive Sales Up 22.4%
May 24, 2010
- Korosho Calls For Cautions for ILD in Patients Receiving Statins
May 24, 2010
- Otsuka HD: Sales of Healthcare Business Up 5.6%
May 24, 2010
- GAMMAGARD Improves Cognitive Function in AD Patients in PII: Baxter
May 24, 2010
- BI Expects 1st Approval for Dabigatran for SPAF in Late 2010
May 17, 2010
- Korosho to Ask for Development of 109 Drugs/Indications
May 17, 2010
- Lixisenatide Significantly Reduces HbA1c: sanofi-aventis
May 17, 2010
- 68% of Public “Don't Know About HPV” Survey
May 17, 2010
- WG to Discuss Regulatory Requirements for Regenerative Medicine
May 17, 2010
- Merck Serono Begins Infertility Treatment Education Program
May 17, 2010
- Exforge to Compete with Takeda's Unisia: Mr Anderson of Novartis
May 17, 2010
- GRU to Call For Lifting on Ban on Supply of Information on Unapproved Drugs
May 17, 2010
- New JMA Leadership to Follow Former Leadership's Policies
May 17, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…